This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Zimmer Biomet (ZBH) Q4 Earnings Top Estimates, Margins Grow
by Zacks Equity Research
Each of Zimmer Biomet's (ZBH) geographic segments records strong year-over-year sales growth on a reported basis, as well as at CER in the fourth quarter.
Haemonetics (HAE) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Haemonetics (HAE) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Haemonetics (HAE) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Haemonetics (HAE) delivered earnings and revenue surprises of 7.22% and 4.13%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
CVS Health (CVS) Q4 Earnings Top Estimates, 2024 EPS View Down
by Zacks Equity Research
Robust sales growth across all three operating segments contributes to CVS Health's (CVS) Q4 revenues.
Edwards Lifesciences (EW) Q4 Earnings Meet, Margins Dip
by Zacks Equity Research
Edwards Lifesciences' (EW) Q4 revenues register year-over-year growth on its strong differentiated portfolio of advanced therapies.
VAREX IMAGING (VREX) Lags Q1 Earnings Estimates
by Zacks Equity Research
VAREX IMAGING (VREX) delivered earnings and revenue surprises of -45.45% and 0.85%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
HAE vs. ABT: Which Stock Is the Better Value Option?
by Zacks Equity Research
HAE vs. ABT: Which Stock Is the Better Value Option?
Edwards Lifesciences (EW) Wins FDA Nod for the EVOQUE System
by Zacks Equity Research
Edwards Lifesciences' (EW) EVOQUE valve replacement system becomes the first transcatheter therapy to earn FDA approval for a tricuspid valve.
Reasons to Retain Quest Diagnostics (DGX) Stock for Now
by Zacks Equity Research
Strength of the base business bodes well for Quest Diagnostics (DGX).
IDEXX (IDXX) Q4 Earnings Surpass Estimates, Margins Fall
by Zacks Equity Research
Across testing modalities, IDEXX (IDXX) achieves strong global growth in the fourth quarter.
Haemonetics (HAE) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Haemonetics (HAE), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.
Hologic's (HOLX) Q1 Earnings Beat Estimates, Gross Margin Down
by Zacks Equity Research
Hologic's (HOLX) Breast Health segment registered strong growth in Q1, primarily owing to higher capital equipment revenues.
Boston Scientific's (BSX) FARAPULSE PFA System Gets FDA Nod
by Zacks Equity Research
Boston Scientific (BSX) secures FDA approval for the FARAPULSE PFA system.
Trinity Biotech (TRIB) to Grow in Wearable Biosensor With Buyout
by Zacks Equity Research
Trinity Biotech's (TRIB) focus on CGM as an initial step, utilizing a device with regulatory approval, provides a de-risked entry point in the wearable biosensor technology space.
3 Stocks to Buy for Consistent Sales Growth
by Derek Lewis
Consistency is key, particularly whenever it concerns generating sales. For those seeking top line compounders, these three companies fit the criteria nicely.
Insulet (PODD) Gains From Product Innovation, Global Expansion
by Zacks Equity Research
Insulet's (PODD) Omnipod 5 continues to be a driving force behind U.S. and international growth.
Haemonetics (HAE) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Quest Diagnostics (DGX) Q4 Revenues Top, Gross Margin Down
by Zacks Equity Research
Quest Diagnostics (DGX) delivers better-than-expected earnings and revenues in the fourth quarter of 2023.
Align Technology (ALGN) Q4 Revenues Top, Margins Expand
by Zacks Equity Research
Align Technology (ALGN) surpasses revenue and earnings estimates in the fourth quarter of fiscal 2023.
Is Haemonetics (HAE) a Solid Growth Stock? 3 Reasons to Think "Yes"
by Zacks Equity Research
Haemonetics (HAE) possesses solid growth attributes, which could help it handily outperform the market.
Boston Scientific (BSX) Q4 Earnings Top, Operating Margin Falls
by Zacks Equity Research
Boston Scientific (BSX) sees an increase in organic and operational revenues in its core business segments and geographies in the reported quarter.
Thermo Fisher (TMO) End Market Growth Strong Despite Macro Woes
by Zacks Equity Research
Thermo Fisher's (TMO) electron microscopy, chromatography and mass spectrometry businesses are delivering strong growth in the academic and government end market.
QIAGEN (QGEN) Forges Alliance to Advance Microbiome Sciences
by Zacks Equity Research
QIAGEN (QGEN) announces a first-in-kind collaboration with Penn State University to help shape research, education and outreach in microbiomes.
Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now
by Zacks Equity Research
Investors continue to be optimistic about IDEXX (IDXX), backed by the strength of the CAG Diagnostics business.